Wall Street Zen Downgrades Lixte Biotechnology (NASDAQ:NMAD) to Sell

Lixte Biotechnology (NASDAQ:NMAD) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings downgraded shares of Lixte Biotechnology from a “sell (e+)” rating to a “sell (e)” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Lixte Biotechnology currently has a consensus rating of “Sell”.

Lixte Biotechnology Price Performance

Shares of Lixte Biotechnology stock opened at $4.30 on Friday. Lixte Biotechnology has a fifty-two week low of $2.36 and a fifty-two week high of $8.38. The firm has a market capitalization of $69.23 million, a P/E ratio of -4.30 and a beta of 1.29. The company’s 50 day moving average price is $7.10 and its two-hundred day moving average price is $5.06.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Equitable Holdings Inc. bought a new position in Lixte Biotechnology in the 2nd quarter valued at approximately $74,000. Axxcess Wealth Management LLC acquired a new stake in Lixte Biotechnology during the 4th quarter worth approximately $54,000. XTX Topco Ltd bought a new stake in Lixte Biotechnology during the 4th quarter worth approximately $57,000. FNY Investment Advisers LLC bought a new stake in Lixte Biotechnology during the 2nd quarter worth approximately $330,000. Finally, Geode Capital Management LLC grew its holdings in Lixte Biotechnology by 25.9% during the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after acquiring an additional 10,722 shares during the last quarter. Institutional investors and hedge funds own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.